

This press release is an English translation of a Japanese-language press release. The official language of this press release is Japanese, and the Japanese version takes precedence over the English version in terms of content and interpretation.

<Press Release>

January 29, 2024

Chordia nominated for the 6th Japan Open Innovation Prize

Kanagawa, Japan, January 29, 2024 – Chordia Therapeutics Inc. (Chordia) is pleased to announce that we have been nominated for the "6th Japan Open Innovation Prize" sponsored by the Cabinet Office for his work on the "Creation of a novel anti-cancer drug MALT1 inhibitor through industry-government-academia collaboration." The prize will be presented at an award ceremony on February 14.

About the 6th Japan Open Innovation Prize

As international competition over the creation of innovation intensifies, a major challenge is to quickly implement the results of research and development and other activities in society, and to link them to the resolution of social needs and the creation of new value. As a way to achieve this, open innovation, which promotes new approaches by combining knowledge, technology, and management resources across organizational boundaries, is attracting attention.

In light of this situation, and in order to further promote open innovation in Japan, the "Japan Open Innovation Awards" are given to initiatives with high leadership and originality that are expected to serve as role models for the future.

About Chordia Therapeutics

Chordia is a clinical stage biotech company based in Fujisawa, Kanagawa Prefecture, Japan. It is engaged in the research and development of novel therapies for cancers. Chordia's lead asset, the CLK inhibitor CTX-712, is under Phase 1 clinical study in Japan and Phase 1/2 clinical study in the US. CTX-712 potentially targets the vulnerability of cancer and is expected to deliver benefit to patients of various types of cancer. In addition to CTX-712, Chordia is engaged in the research of several preclinical assets, including CTX-439, a CDK12 inhibitor, which is expected to be effective in cancers with specific abnormalities, as well as GCN2 inhibitors.

Established: November 2017
Address: 26-1, Muraoka-Higashi 2-chome, Fujisawa,
Kanagawa 251-0012, Japan
Representative: Hiroshi Miyake, Representative Director
Website: <https://www.chorditherapeutics.com/en/>

For more information, contact IR, Mizobe: ir@chorditherapeutics.com